167 related articles for article (PubMed ID: 37402881)
21. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.
Huang X; Zhang Y; Tang Y; Butler N; Kim J; Guessous F; Schiff D; Mandell J; Abounader R
Neoplasia; 2013 Aug; 15(8):952-65. PubMed ID: 23908595
[TBL] [Abstract][Full Text] [Related]
22. [Expression of Runx3 and C-myc in human colorectal cancer].
Zheng W; Zheng K; Zhong L; Li Q; Huang Z
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jun; 34(7):1042-7. PubMed ID: 25057081
[TBL] [Abstract][Full Text] [Related]
23. C/EBPalpha regulation of the growth-arrest-associated gene gadd45.
Constance CM; Morgan JI; Umek RM
Mol Cell Biol; 1996 Jul; 16(7):3878-83. PubMed ID: 8668205
[TBL] [Abstract][Full Text] [Related]
24. Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.
Walia MK; Ho PM; Taylor S; Ng AJ; Gupte A; Chalk AM; Zannettino AC; Martin TJ; Walkley CR
Elife; 2016 Apr; 5():. PubMed ID: 27070462
[TBL] [Abstract][Full Text] [Related]
25. Tumor suppressing role of serum-derived exosomal microRNA-15a in osteosarcoma cells through the GATA binding protein 2/murine double minute 2 axis and the p53 signaling pathway.
Wu C; Li Z; Feng G; Wang L; Xie J; Jin Y; Wang L; Liu S
Bioengineered; 2021 Dec; 12(1):8378-8395. PubMed ID: 34592889
[TBL] [Abstract][Full Text] [Related]
26. Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells.
Tsuda Y; Tanikawa C; Miyamoto T; Hirata M; Yodsurang V; Zhang YZ; Imoto S; Yamaguchi R; Miyano S; Takayanagi H; Kawano H; Nakagawa H; Tanaka S; Matsuda K
Sci Rep; 2017 Sep; 7(1):10739. PubMed ID: 28878391
[TBL] [Abstract][Full Text] [Related]
27. C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes.
Yoon K; Smart RC
Mol Cell Biol; 2004 Dec; 24(24):10650-60. PubMed ID: 15572670
[TBL] [Abstract][Full Text] [Related]
28. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
30. p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y.
Hackzell A; Uramoto H; Izumi H; Kohno K; Funa K
J Biol Chem; 2002 Oct; 277(42):39769-76. PubMed ID: 12167641
[TBL] [Abstract][Full Text] [Related]
31. The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo.
Samsa WE; Mamidi MK; Bashur LA; Elliott R; Miron A; Chen Y; Lee B; Greenfield EM; Chan R; Danielpour D; Zhou G
Oncogene; 2020 Jun; 39(23):4581-4591. PubMed ID: 32390003
[TBL] [Abstract][Full Text] [Related]
32. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
33. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.
Si J; Yu X; Zhang Y; DeWille JW
Mol Cancer; 2010 Apr; 9():92. PubMed ID: 20426839
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.
Kim H; Yoo S; Zhou R; Xu A; Bernitz JM; Yuan Y; Gomes AM; Daniel MG; Su J; Demicco EG; Zhu J; Moore KA; Lee DF; Lemischka IR; Schaniel C
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):E11128-E11137. PubMed ID: 30385632
[TBL] [Abstract][Full Text] [Related]
35. Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma.
Rao PH; Zhao S; Zhao YJ; Yu A; Rainusso N; Trucco M; Allen-Rhoades W; Satterfield L; Fuja D; Borra VJ; Man TK; Donehower LA; Yustein JT
Genes Chromosomes Cancer; 2015 Dec; 54(12):796-808. PubMed ID: 26355645
[TBL] [Abstract][Full Text] [Related]
36. Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias.
Fuchs O
Folia Biol (Praha); 2007; 53(3):97-108. PubMed ID: 17580000
[TBL] [Abstract][Full Text] [Related]
37. A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells.
Shin MH; He Y; Marrogi E; Piperdi S; Ren L; Khanna C; Gorlick R; Liu C; Huang J
PLoS Genet; 2016 Feb; 12(2):e1005884. PubMed ID: 26925584
[TBL] [Abstract][Full Text] [Related]
38. Context-dependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells.
Ju X; Ishikawa TO; Naka K; Ito K; Ito Y; Oshima M
Cancer Sci; 2014 Apr; 105(4):418-24. PubMed ID: 24447505
[TBL] [Abstract][Full Text] [Related]
39. C/EBPα poises B cells for rapid reprogramming into induced pluripotent stem cells.
Di Stefano B; Sardina JL; van Oevelen C; Collombet S; Kallin EM; Vicent GP; Lu J; Thieffry D; Beato M; Graf T
Nature; 2014 Feb; 506(7487):235-9. PubMed ID: 24336202
[TBL] [Abstract][Full Text] [Related]
40. Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients.
Wu X; Cai ZD; Lou LM; Zhu YB
Cancer Epidemiol; 2012 Apr; 36(2):212-6. PubMed ID: 21890444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
